Vol 67, No 2 (2016)
Review paper
Published online: 2016-02-17

open access

Page views 2201
Article views/downloads 2665
Get Citation

Connect on Social Media

Connect on Social Media

Mouse models of papillary thyroid carcinoma — short review

Dagmara Rusinek, Jolanta Krajewska, Michał Jarząb
DOI: 10.5603/EP.a2016.0042
Pubmed: 27082155
Endokrynol Pol 2016;67(2):212-223.

Abstract

Thyroid carcinoma (TC) is the most common endocrine malignancy, and its frequency is still rising. Papillary thyroid carcinoma (PTC) accounts for 80% of all TCs and usually is related to a very good prognosis. However, the standard therapeutic approaches are not always sufficient and disease progression is sometimes observed. These data highlight the limitation of our understanding of molecular mechanisms underlying tumorigenesis and how they vary between individual patients. Over the last 19 years mouse models of thyroid cancers have been developed in order to give answers to questions about their genetic background, relations of key molecular events with pathways fundamental for cancer, and many others. Among these models genetically engineered mice were of utmost importance regarding the input of knowledge about human tumorigenesis. In the present review the most significant mouse models of PTC are described with particular emphasis on BRAFV600E-induced ones, for the sake of its frequency in PTC, relation to factors of poor prognosis, and the fact that, since its identification, it became an attractive target in novel therapies. For the presented mouse models phenotype consequences of particular genetic alterations are described as well as the limitations of the used methods. (Endokrynol Pol 2016; 67 (2): 212–223)